Abstracts tagged "lipids and rheumatoid arthritis (RA)"

Abstract Number: 497 • 2018 ACR/ARHP Annual Meeting
Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
Ilana Golub¹, Jennifer Wang², Ani Shahbazian¹, John Moriarty¹ and Christina Charles-Schoeman³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have a marked increase in cardiovascular (CV) morbidity and mortality compared to the general population. Conventional lipid profiles are…
Abstract Number: 1484 • 2016 ACR/ARHP Annual Meeting
Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Saurash Reddy, Xiaobo Meng and Carol Hitchon, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis (RA) has been established as a risk factor for cardiovascular disease (CVD), with systemic inflammation being linked with atherosclerosis. Traditional CVD risk…
Abstract Number: 2051 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis
Heidi Kokkonen¹, Lisbeth Ärlestig² and Solbritt Rantapää-Dahlqvist^3,4, ¹Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁴Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) comorbidity compared with the general population. Contradictory results concerning CV disease…
Abstract Number: 2263 • 2016 ACR/ARHP Annual Meeting
Apolipoprotein E Regulates Inflammation and Joint Destruction during Antigen-Induced Arthritis (AIA)
Giuliana Ascone¹, Irene Di Ceglie¹, Wouter de Munter¹, Birgitte Walgreen², Annet Sloetjes¹, Peter M. van der Kraan¹, Ernst Lindhout³, Mike Martens³ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental, Radboud university medical center, Nijmegen, Netherlands, ³Future Diagnostics Solutions (FDs), Wijchen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease largely driven by immune complexes and their interaction with FcγRs present on macrophages within the synovium.…
Abstract Number: 2549 • 2016 ACR/ARHP Annual Meeting
Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients
Maria Vanesa Hernandez-Hernandez¹, Esmeralda Delgado-Frias², Beatriz Tejera³, Cristina Luna Gomez⁴, Jose Ramon Muñiz^5,6, De Vera-González AM⁷, Sagrario Bustabad⁸, Ivan Ferraz-Amaro⁸ and Federico Díaz-González⁹, ¹Rheumatology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ²Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ³Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁴Rosario S/N, H. Ntra. Sra. La Candelaria, Santa Cruz de Teneri, Spain, ⁵Radiology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ⁶Radiology, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁷Central Laboratory Division, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁹Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) has been acknowledged to increase cardiovascular mortality probably due, in part, to a lipid profile different from that observed in the…
Abstract Number: 2607 • 2016 ACR/ARHP Annual Meeting
Favorable Changes in Lipid Profile with Additive DMARD Therapy in Rheumatoid Arthritis Patients Failing Methotrexate Monotherapy
Tate Johnson¹, Ted R Mikuls², Harlan Sayles¹, Michael J. Duryee³, Geoffrey M. Thiele¹, Mary Brophy^4,5 and James R. O'Dell⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁶Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease is a significant comorbidity among RA patients. As such, dyslipidemia and the effect of DMARD therapy on lipid profiles is an important…
Abstract Number: 2633 • 2016 ACR/ARHP Annual Meeting
Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis
Fabio Cacciapaglia¹, Simone Perniola¹, Mariangela Nivuori¹, Margherita Giannini¹, Olga Magazzino¹, Maria Giannotta¹, Florenzo Iannone² and Giovanni Lapadula¹, ¹Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, General Hospital, Bari, Italy, ²Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, General Hospital, Bari, Italy
Background/Purpose: o examine any change between different biologic agents on lipid profile of RA patients. Methods: Patients affected by RA, according to the 2010 EULAR/ACR…
Abstract Number: 3093 • 2016 ACR/ARHP Annual Meeting
Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial
Alexandre Virone¹, Jean-Philippe Bastard², Soraya Fellahi², Jacqueline Capeau², Stéphanie Rouanet³, Jean Sibilia⁴, Philippe Ravaud⁵, Francis Berenbaum⁶, Jacques-Eric Gottenberg⁷ and Jeremie Sellam⁶, ¹Rheumatology, Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ²APHP Hôpital Tenon, Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, DHU i2B, Paris, France, ³StatEthic, Levallois-Perret, France, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Hôpital Hôtel Dieu, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Considering the increased cardiovascular risk in RA patients and the influence of biologics, especially tocilizumab (TCZ) on the lipid profile, we aimed to investigate…
Abstract Number: 1474 • 2016 ACR/ARHP Annual Meeting
Increased Levels of Lipoprotein(a) in RA Patients with Cardiovascular Disease
Sverre Holm^1,2, Ingvild Oma³, Tor-Arne Hagve⁴, Kjell Saatvedt⁵, Knut Mikkelsen⁶, Hans Rydningen⁷, Sven Martin Almdahl⁸, Pål Aukrust^9,10, Bente Halvorsen^9,11 and Ivana Hollan^6,12,13,14, ¹Hospital For Rheumatic Diseases, Lillehammer, Norway, ²Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ³Innlandet Hospital Trust, Lillehammer, Norway, ⁴Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁷Feiring Heart Clinic, Feiring, Norway, ⁸Department of Cardiothoracic Surgery, University Hospital of North Norway, Tromsø, Norway, ⁹Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ¹⁰Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹¹Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹²Department of Medicine, Brigham and Women’s Hospital, Boston, MA, ¹³Harvard Medical School, Boston, MA, ¹⁴Department of Medicine, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with various inflammatory rheumatic diseases (IRD) have increased cardiovascular morbidity caused by atherosclerosis. The aetiology of the accelerated atherosclerosis in IRD is still…
Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
Myriam Guevara¹, Bernard NG¹ and Nancy Gove², ¹Rheumatology, University of Washington, Seattle, WA, ²Biostatistics, Seattle Children's, Seattle, WA
Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…
Abstract Number: 1508 • 2015 ACR/ARHP Annual Meeting
Lipid Target Achievement Among Patients with Recent-Onset Rheumatoid Arthritis during the First Six Years of Follow-up: Results from a French Multicenter Cohort of Early Arthritis
Anne Tournadre¹, Bruno Pereira², Jean-Jacques Dubost³, Nathalie Rincheval⁴, Anne-Christine Rat^5,6, Bernard Combe⁷ and Martin Soubrier³, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴Lapeyronie Hospital, Montpellier I University, UMR 5535, EA2415, Montpellier, France, ⁵CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁶CHU de Nancy, Rheumatology, Nancy, France, ⁷Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Cardiovascular mortality is increased in rheumatoid arthritis (RA) and RA is an independent risk factor leading to a rapid increase in risk following diagnosis.…
Abstract Number: 1510 • 2015 ACR/ARHP Annual Meeting
The Association Between HDL Cholesterol Efflux Capacity, Citrullinated ApoA1 and Anti-Citrullinated ApoA1 Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jing Cui¹, Christopher Rhodes², Lauren J. Lahey², Martin Playford³, I-Hsin Kuo¹, Michelle Frits¹, Christine Iannaccone¹, Jonathan S. Coblyn⁴, Michael Weinblatt¹, Nancy Shadick⁵, Nehal N. Mehta³ and Jeremy Sokolove², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³NHLBI, National Institutes of Health, Bethesda, MD, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures how well HDL particles remove cholesterol from lipid-laden macrophages, such as those found in atherosclerotic plaques. …
Abstract Number: 1545 • 2015 ACR/ARHP Annual Meeting
Comparison of Statin Eligibility According to the Adult Treatment Panel III, ACC/AHA Blood Cholesterol Guideline and Presence of Carotid Plaque By Ultrasound in Hispanics with Rheumatoid Arthritis
Alberto Cardenas-de La Garza¹, Raymundo Vera-Pineda², Dionicio A. Galarza-Delgado¹, Jose Ramon Azpiri-Lopez³, Iris J. Colunga-Pedraza¹, Jesus Zacarias Villarreal-Pérez⁴, Griselda Serna-Peña⁵ and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ³Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Endocrinology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Internal Medicine, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Atherosclerotic cardiovascular disease (ASCVD) is the number one cause of death in rheumatoid arthritis (RA) patients. RA itself is an independent risk factor for…
Abstract Number: 1547 • 2015 ACR/ARHP Annual Meeting
Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients
Anand Kumthekar¹, Michail Alevizos², Nicole Jordan³ and Anna R. Broder⁴, ¹Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ³Montefiore Medical Center, New York, NY, ⁴Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death among individuals with rheumatoid arthritis (RA). The 2010 EULAR guidelines recommend annual CV risk assessment…
Abstract Number: 2127 • 2015 ACR/ARHP Annual Meeting
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Subclinical Coronary Atherosclerosis Is Higher Among Rheumatoid Arthritis Patients with the Lowest Circulating Low Density Lipoprotein Concentrations Compared with Controls
Jon T. Giles¹, Mary Chester M. Wasko², Cecilia P. Chung³, Amy Kao⁴, Sabahat Bokhari⁵, Afshin Zartoshti⁶, C. Michael Stein⁷ and Joan M. Bathon^8,9, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ³Division of Rheumatology & Immunology, Vanderbilt University School of Medicine, Nashville, TN, ⁴Biogen, Cambridge, MA, ⁵Cardiology, Columbia University Medical Center, NY, NY, ⁶Rheumatology, Columbia University Medical Center, NY, NY, ⁷Div of Clinical Pharmacology, Vanderbilt University, Nashville, TN, ⁸Medicine, Columbia University, College, New York, NY, ⁹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Several recent studies have identified RA patients with very low levels of circulating total and low density lipoprotein cholesterol (LDL-C) to be at particularly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].